NanoViricides, Inc. announced that a Phase II clinical trial of its antiviral candidate NV-387 for the treatment of MPox is expected to begin soon in the Democratic Republic of Congo. Site preparation and staff training are scheduled for early April 2026 for the study, which has already received approval from DRC regulatory authorities. The trial will evaluate the safety and effectiveness of NV-387 against Clade I MPox as the company advances regulatory development and seeks Orphan Drug Designation from the U.S. Food and Drug Administration.
The company's lead drug candidate, NV-387, represents a broad-spectrum antiviral drug that NanoViricides plans to develop as a treatment for multiple respiratory viral infections including RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, in addition to MPox and Smallpox infections. This multi-target approach positions NV-387 as a potentially versatile therapeutic platform that could address several significant public health challenges simultaneously.
NanoViricides' technology platform is based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc., with the company holding a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The company's business model centers on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Additional information about the company's technology and approach is available at https://www.nanoviricides.com.
The company's development pipeline extends beyond NV-387 to include NV-HHV-1 for the treatment of Shingles and drugs against numerous other viral diseases including oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. NanoViricides holds worldwide exclusive perpetual licenses to TheraCour's nanomedicine technology for several drugs targeting specific viral diseases, with intentions to obtain additional licenses for RSV, Poxviruses, and/or Enteroviruses if initial research proves successful.
For business and technology leaders monitoring antiviral development, NanoViricides' approach represents a potentially disruptive innovation in infectious disease treatment. The company's platform technology could enable more rapid development of treatments for emerging viral threats, reducing the typical lengthy development timeline associated with traditional pharmaceutical approaches. The planned MPox trial in the DRC, where Clade I MPox is endemic, provides a real-world testing ground that could yield valuable data about the drug's effectiveness in high-transmission environments.
The company's regulatory strategy includes seeking Orphan Drug Designation from the FDA, which could provide market exclusivity and development incentives if granted. This approach demonstrates how smaller biotech firms can navigate complex regulatory landscapes while advancing potentially transformative therapies. The broader implications extend to pandemic preparedness, as successful development of broad-spectrum antivirals like NV-387 could provide healthcare systems with versatile tools to combat multiple viral threats rather than developing separate treatments for each pathogen.
Investors and industry observers can find additional information about NanoViricides' developments through the company's newsroom at https://ibn.fm/NNVC. The successful execution of the Phase II MPox trial could validate NanoViricides' platform technology and potentially accelerate development of its broader antiviral portfolio, making this upcoming clinical milestone significant for both the company and the broader antiviral therapeutics sector.
